TABLE 7.
Highly co-cited literature (top 10).
| Rank | Title | Journal | Author | Citations |
|---|---|---|---|---|
| 1 | FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer | New Engl J Med | Conroy T, et al. | 573 |
| 2 | Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial | J Clin Oncol | Burris HA, et al. | 548 |
| 3 | Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine | New Engl J Med | Von Hoff DD, et al. | 521 |
| 4 | Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group | J Clin Oncol | Moore MJ, et al. | 308 |
| 5 | Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States | Cancer Res | Rahib L, et al. | 307 |
| 6 | Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer | Science | Olive KP, et al. | 265 |
| 7 | Cancer statistics, 2007 | CA-Cancer J Clin | Jemal A, et al. | 237 |
| 8 | Gemcitabine resistance in pancreatic ductal adenocarcinoma | Drug Resist Update | Binenbaum Y, et al. | 174 |
| 9 | Pancreatic cancer | Nat Rev Dis Primers | Kleeff J, et al. | 162 |
| 10 | FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer | New Engl J Med | Conroy T, et al. | 158 |